Disease-Free Survival is a Promising Surrogate for Overall Survival in Colorectal Cancer Studies
Menée à partir de données portant sur 18 396 patients atteints d'un cancer du côlon et inclus dans des essais cliniques évaluant une chimiothérapie adjuvante (âge médian : 59 ans ; 54 % d'hommes), cette étude évalue l'association entre la survie sans progression à 3 ans et la survie globale à 5 ans
I congratulate Yin, et al. (1) for their well-conducted study validating the surrogacy of 3-year disease-free survival (DFS) for 5-year overall survival (OS) in the setting of adjuvant colorectal cancer studies. The thankfully long survival time in this setting makes phase 3 trials long and costly, requiring extensively long follow up times to rigorously assess efficacy in reducing OS. Thus, the identification and validation of earlier surrogate endpoints is of high clinical significance in this setting, and 3-year DFS is a practical choice.
Journal of the National Cancer Institute , éditorial en libre accès, 2020